The Zhitong Finance App learned that according to the Hong Kong Stock Exchange disclosure on December 4, Hangzhou Gaoguang Pharmaceutical Co., Ltd. (hereinafter: Gaoguang Pharmaceutical) submitted a statement to the main board of the Hong Kong Stock Exchange, with CICC and CMB International as co-sponsors. According to the prospectus, Gaoguang Pharmaceutical is a key innovative enterprise dedicated to exploring and developing safe and effective treatments for patients with autoimmune/inflammatory diseases around the world, and has established a unique advantage in the highly challenging field of neuroinflammation with world-class drug candidates for the treatment of Alzheimer's disease and Parkinson's disease. With end-to-end internal capabilities from target selection and drug candidate discovery to clinical development, the company has built a differentiated asset portfolio (covering a variety of autoimmune diseases and neurodegenerative disease indications), including four clinical-stage drug candidates and multiple pre-clinical drug candidates.

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange disclosure on December 4, Hangzhou Gaoguang Pharmaceutical Co., Ltd. (hereinafter: Gaoguang Pharmaceutical) submitted a statement to the main board of the Hong Kong Stock Exchange, with CICC and CMB International as co-sponsors. According to the prospectus, Gaoguang Pharmaceutical is a key innovative enterprise dedicated to exploring and developing safe and effective treatments for patients with autoimmune/inflammatory diseases around the world, and has established a unique advantage in the highly challenging field of neuroinflammation with world-class drug candidates for the treatment of Alzheimer's disease and Parkinson's disease. With end-to-end internal capabilities from target selection and drug candidate discovery to clinical development, the company has built a differentiated asset portfolio (covering a variety of autoimmune diseases and neurodegenerative disease indications), including four clinical-stage drug candidates and multiple pre-clinical drug candidates.